Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabigatran + rivaroxaban + apixaban
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is not a single combination drug but rather three separate direct oral anticoagulants (DOACs). Dabigatran is a direct thrombin (factor IIa) inhibitor, while rivaroxaban and apixaban are factor Xa inhibitors. These medications are used primarily for prevention of stroke and systemic embolism in non-valvular atrial fibrillation and for treatment and prevention of venous thromboembolism.
- Brand names
- Pradaxa + Xarelto + Eliquis
- Other names
- Direct Oral AnticoagulantsDOACsNOACsNon-vitamin K antagonist oral anticoagulants
02
Targets
F10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on dabigatran + rivaroxaban + apixaban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabigatran + rivaroxaban + apixaban.